Analysis of safety and pharmacodynamics of SANA in human volunteers Based on all the accumulated preclinical evidence supporting that SANA might be a suitable first-in-class drug for treatment of obesity and comorbidities, we performed a randomized, double-blind, placebo-controlled phase 1A/B clinical trial in healthy lean volunteers and in volunteers with obesity
Statistical analyses included paired t -tests, Wilcoxon signed-rank tests, and chi-squared tests
Individuals with Gastrointestinal Conditions: Certain gastrointestinal conditions, such as celiac disease, Crohns disease, or gastrointestinal surgery, can impair nutrient absorption
These medications also impact hunger hormones, so people taking them do not think about food as much, which makes it easier to make healthier food choices
doi: 10.4149/neo_2020_200707N705 89 YangWHHuangZWuJDingCCMurphySKChiJT
Histology and immunohistochemistry Tissues were fixed in 4% paraformaldehyde solution in phosphate buffer for 12 h, placed in 20% sucrose overnight, embedded in Tissue-Tek (SAKURA) and stored at 80 C until use